These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37072380)

  • 1. A patent review of PRMT5 inhibitors to treat cancer (2018 - present).
    Gao J; Yang J; Xue S; Ding H; Lin H; Luo C
    Expert Opin Ther Pat; 2023 Apr; 33(4):265-292. PubMed ID: 37072380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer.
    Guo C; Wu L; Zheng X; Zhao L; Hou X; Wang Z; Han C
    Curr Top Med Chem; 2023; 23(21):2048-2074. PubMed ID: 37438905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein arginine methyltransferase 5: a potential cancer therapeutic target.
    Yuan Y; Nie H
    Cell Oncol (Dordr); 2021 Feb; 44(1):33-44. PubMed ID: 33469838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
    Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
    Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms.
    Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q
    Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022).
    Dong J; Duan J; Hui Z; Garrido C; Deng Z; Xie T; Ye XY
    Expert Opin Ther Pat; 2022 Dec; 32(12):1185-1205. PubMed ID: 36594709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A patent review of arginine methyltransferase inhibitors (2010-2018).
    Li X; Wang C; Jiang H; Luo C
    Expert Opin Ther Pat; 2019 Feb; 29(2):97-114. PubMed ID: 30640571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
    Fu S; Zheng Q; Zhang D; Lin C; Ouyang L; Zhang J; Chen L
    Eur J Med Chem; 2022 Dec; 244():114842. PubMed ID: 36274274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer.
    Liu S; Liu Z; Piao C; Zhang Z; Kong C; Yin L; Liu X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):293. PubMed ID: 36199122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
    Wang Y; Hu W; Yuan Y
    J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.
    Zheng J; Li B; Wu Y; Wu X; Wang Y
    J Med Chem; 2023 Jul; 66(13):8407-8427. PubMed ID: 37366223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
    Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting protein arginine methyltransferase 5 in disease.
    Richters A
    Future Med Chem; 2017 Nov; 9(17):2081-2098. PubMed ID: 29076773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRMT5: a putative oncogene and therapeutic target in prostate cancer.
    Beketova E; Owens JL; Asberry AM; Hu CD
    Cancer Gene Ther; 2022 Mar; 29(3-4):264-276. PubMed ID: 33854218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
    Prabhu L; Wei H; Chen L; Demir Ö; Sandusky G; Sun E; Wang J; Mo J; Zeng L; Fishel M; Safa A; Amaro R; Korc M; Zhang ZY; Lu T
    Oncotarget; 2017 Jun; 8(25):39963-39977. PubMed ID: 28591716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
    Alinari L; Mahasenan KV; Yan F; Karkhanis V; Chung JH; Smith EM; Quinion C; Smith PL; Kim L; Patton JT; Lapalombella R; Yu B; Wu Y; Roy S; De Leo A; Pileri S; Agostinelli C; Ayers L; Bradner JE; Chen-Kiang S; Elemento O; Motiwala T; Majumder S; Byrd JC; Jacob S; Sif S; Li C; Baiocchi RA
    Blood; 2015 Apr; 125(16):2530-43. PubMed ID: 25742700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
    Lin H; Luengo JI
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1264-1269. PubMed ID: 30956011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis and Biological Evaluation of Novel and Potent Protein Arginine Methyltransferases 5 Inhibitors for Cancer Therapy.
    Tang Y; Huang S; Chen X; Huang J; Lin Q; Huang L; Wang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Arginine Methyltransferase 5 (PRMT5) Mutations in Cancer Cells.
    Rasheed S; Bouley RA; Yoder RJ; Petreaca RC
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.